Oxidative Stress and Proteinopathy in Alzheimer's Disease

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 126

Special Issue Editor

E-Mail Website
Guest Editor
School of Life Sciences, Kyungpook National University, Daegu 41566, Republic of Korea
Interests: glial mediated neuroinflammation in AD; oxidative stress as a AD contributing factor; gene therapy as a treatment for aging and neurodegenerative disordres

Special Issue Information

Dear Colleagues,

The multifactorial nature of Alzheimer’s disease (AD) has given rise to several research debates on the early events that led to AD. Of note, interrogation of post-mortem AD brain and several neuroimaging studies has revealed accumulation and misfolding of certain proteins (prominantely amyloid beta and tau) as the important primary event playing a significant role in the initiation and progression of the disease. This is of particular relevance since this results in synaptic dysfunction and loss, leading to cognitive decline and ultimately results in neuronal cell death. An intriguing and complex relationship has been shown between Aβ and mitochondrial dysfunction, redox metal imbalance, failure of protein clearance mechanism, advanced glycation end-products, and calcium excitotoxicity that may further contribute to the oxidative stress in the brains of AD patients. This results in the accumulation of free radicals and respiratory chain defects that consequently participate in the formation of excess free radicals, as well as extracellular Aβ deposits that induce local inflammatory processes and activate glial cell, another potential source of ROS, and reduction in antioxidant defense mechanism, thus creating a vicious cycle. Understanding these interactions may thus aid in the identification of potential neuroprotective therapies that could be clinically useful. 

Dr. Chanchal Sharma
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Alzheimer’s disease
  • oxidative stress
  • synaptic dysfunction
  • abnormal protein accumulation
  • gliosis
  • neuroinflammation
  • antioxidant therapies

Published Papers

This special issue is now open for submission.
Back to TopTop